Trimipramine (or SURMONTIL®) is mainly prescribed to treat major depressive disorder, acute anxiety, and insomnia.
Class: Tricyclic (TCA)
FDA Approval: 1979
Dosage Forms: 25 mg, 50 mg, 100 mg
Biological Half-life: 23-24 hours
Side Effects: Dizziness, sleepiness, dry mouth, blurred vision, constipation, diarrhea, tingly sensation, weakness, lack of coordination, appetite changes, low libido, increased suicide risk
Routes of Administration: Oral, IM, IV
Pregnancy Category: C (US)